Literature DB >> 11605815

Characteristics of patients with Burkholderia cepacia bacteremia.

C H Huang1, T N Jang, C Y Liu, C P Fung, K W Yu, W W Wong.   

Abstract

Burkholderia cepacia has become an important pathogen of infections in immunocompromised and nosocomial patients. The characteristics of 42 episodes of B. cepacia bacteremia in 40 patients admitted to the Taipei Veterans General Hospital between January 1997 and December 1999 were retrospectively analyzed. Factors that adversely influenced the mortality rate included respiratory failure, an unknown infection source, a period in an intensive care unit, and shock. Most of the patients had serious underlying diseases, such as diabetes mellitus, malignancy, congestive heart failure, and chronic obstructive pulmonary disease. The mean time for a positive blood culture was 45 days after admission. The overall mortality rate was 28.6% (12/42), and 44.4% (12/27) of all deaths were directly related to B. cepacia bacteremia. Polymicrobial bacteremia was found in 5 patients. Ceftazidime was the most effective antimicrobial agent in vitro, whereas chloramphenicol, imipenem, and trimethoprim/sulfamethoxazole were less effective alternatives. Appropriate antibiotic therapy was given to 30 patients, most of whom responded to the therapy except for 5 who died despite receiving appropriate treatment. Although B. cepacia infection develops in a relatively small proportion of hospitalized individuals, it has a major impact on morbidity and mortality. In view of the fact that B. cepacia develops resistance to a wide range of antimicrobial agents, ceftazidime and/or trimethoprim/sulfamethoxazole should be the drug of choice for empiric therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11605815

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  18 in total

Review 1.  Advances in electronic-nose technologies developed for biomedical applications.

Authors:  Alphus D Wilson; Manuela Baietto
Journal:  Sensors (Basel)       Date:  2011-01-19       Impact factor: 3.576

Review 2.  Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.

Authors:  Nadim G El Chakhtoura; Elie Saade; Alina Iovleva; Mohamad Yasmin; Brigid Wilson; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2018-01-16       Impact factor: 5.091

3.  First isolation of Burkholderia cepacia from a deep neck abscess in a diabetic patient successfully treated with hyperbaric oxygen.

Authors:  Gian Paolo Fadini; Antonio Tiengo; Angelo Avogaro
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

4.  An outbreak of Burkholderia cenocepacia bacteremia in immunocompromised oncology patients.

Authors:  T Mann; D Ben-David; A Zlotkin; D Shachar; N Keller; A Toren; A Nagler; G Smollan; A Barzilai; G Rahav
Journal:  Infection       Date:  2010-04-01       Impact factor: 3.553

5.  Pharmacokinetics and efficacies of liposomal and conventional formulations of tobramycin after intratracheal administration in rats with pulmonary Burkholderia cepacia infection.

Authors:  Jean-Francois Marier; Jean Lavigne; Murray P Ducharme
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

6.  Experimental adaptation of Burkholderia cenocepacia to onion medium reduces host range.

Authors:  Crystal N Ellis; Vaughn S Cooper
Journal:  Appl Environ Microbiol       Date:  2010-02-12       Impact factor: 4.792

7.  Burkholderia cenocepacia bacteremia without respiratory colonization in an adult intensive care unit: epidemiological and molecular investigation of an outbreak.

Authors:  M Katsiari; Z Roussou; K Tryfinopoulou; Ac Vatopoulos; Ed Platsouka; A Maguina
Journal:  Hippokratia       Date:  2012-10       Impact factor: 0.471

8.  Burkholderia cepacia Exit-Site Infection in Peritoneal Dialysis Patients-Clinical Characteristics and Treatment Outcomes.

Authors:  Desmond Y H Yap; Jasper F W Chan; Terence Yip; Maggie M Y Mok; Lorraine P Y Kwan; Wai Kei Lo; Tak Mao Chan
Journal:  Perit Dial Int       Date:  2015-10-22       Impact factor: 1.756

9.  A 17-Year Nationwide Study of Burkholderia cepacia Complex Bloodstream Infections Among Patients in the United States Veterans Health Administration.

Authors:  Nadim G El Chakhtoura; Elie Saade; Brigid M Wilson; Federico Perez; Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2017-10-15       Impact factor: 9.079

10.  Burkholderia cepacia infection in a non-cystic fibrosis patient: an arcane presentation.

Authors:  Sufyan Ibrahim; Haritha Madigubba; Himanshu Y N; Kiran Chawla
Journal:  Access Microbiol       Date:  2021-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.